Novartis AG ADR (NVS)vsNexgel Inc (NXGL)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
NXGL
Nexgel Inc
$0.59
-1.63%
HEALTHCARE · Cap: $5.14M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 495286% more annual revenue ($56.58B vs $11.42M). NVS leads profitability with a 23.9% profit margin vs -26.3%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
NXGL
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+76.8%
Fair Value
$6.04
Current Price
$0.59
$5.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -52.7% — below average capital efficiency
Revenue declined 8.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : NXGL
The strongest argument for NXGL centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : NXGL
The primary concerns for NXGL are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while NXGL is a turnaround play — different risk/reward profiles.
NXGL carries more volatility with a beta of 0.85 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 23.9% margins. NXGL offers better value entry with a 76.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Nexgel Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
NEXGEL, Inc. manufactures aqueous, electron beam crosslinked, high water content hydrogels and polymeric gels. The company is headquartered in Langhorne, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?